Previous studies have shown that endothelial nitric oxide (NO) synthase (eNOS)-derived NO is an important signaling molecule in ischemia-reperfusion (I-R) injury. Deficiency of eNOS-derived NO has been shown to exacerbate injury in hepatic and myocardial models of I-R. We hypothesized that transgenic overexpression of eNOS (eNOS-TG) would reduce hepatic I-R injury. We subjected two strains of eNOS-TG mice to 45 min of hepatic ischemia and 5 h of reperfusion. Both strains were protected from hepatic I-R injury compared with wild-type littermates. Because the mechanism for this protection is still unclear, additional studies were performed by using inhibitors and activators of both soluble guanylyl cyclase (sGC) and heme oxygenase-1 (HO-1) enzymes. Blocking sGC with 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) and HO-1 with zinc (III) deuteroporphyrin IX-2,4-bisethyleneglycol (ZnDPBG) in wildtype mice increased hepatic I-R injury, whereas pharmacologically activating these enzymes significantly attenuated I-R injury in wildtype mice. Interestingly, ODQ abolished the protective effects of eNOS overexpression, whereas ZnDPBG had no effect. These results suggest that hepatic protection in eNOS-TG mice may be mediated in part by NO signaling via the sGC-cGMP pathway and is independent of HO-1 signal transduction pathways. nitric oxide; heme oxygenase-1; soluble guanyly cyclase; phosphodiesterase type 5 inhibition; endothelial nitric oxide synthase HEPATIC ISCHEMIA-REPERFUSION (I-R) injury occurs in many clinical settings, including liver resection, liver transplantation, hemorrhagic shock, septic shock, and cardiogenic shock (15). Liver transplantation has been on the rise over the last fifteen years, prompting an increasing need to better understand the pathogenic mechanisms of hepatic I-R injury and to develop novel means of hepatic protection.One therapeutic approach, of recent interest, to minimize I-R injury, is the enhancement of nitric oxide (NO) bioavailability. NO is a product of the oxidative conversion of L-arginine to citrulline via the enzyme endothelial NO synthase (eNOS). NO is of physiological importance because of its involvement in cardiovascular homeostasis. NO fulfills many physiological roles including acting as a vasodilator by relaxing vascular smooth muscle cells (17, 29), inhibiting platelet aggregation (30), leuckocyte adhesion (25), and general inflammation (27).Although the role of NO in hepatic I-R injury has been controversial with a number of studies (3) that cite the protective and deleterious effects of NO therapy, it is now generally accepted that eNOS-derived NO is cytoprotective in I-R injury (4, 37). Studies (24, 37) have shown that eNOS significantly contributes to the cytoprotection of hepatic tissue against I-R injury and that injury is exacerbated in eNOS-deficient mice (16, 19). In correlation, eNOS overexpression has been reported (20) to reduce I-R injury.The aim of the present study was to investigate the effects of chronic genetic overexpression of eNOS on the severit...